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1. BACKGROUND {#brb31313-sec-0005}
=============

Leukodystrophy is a group of hereditary leukoencephalopathies characterized by lesions in white matter (van der Knaap & Bugiani, [2017](#brb31313-bib-0014){ref-type="ref"}; Vanderver et al., [2015](#brb31313-bib-0015){ref-type="ref"}), which can be detected by magnetic resonance imaging (MRI) (Di Donato, Dotti, & Federico, [2014](#brb31313-bib-0003){ref-type="ref"}). This disease is manifested by pyramidal and extrapyramidal signs, mental and behavior disorders, cognitive decline (Lynch et al., [2016](#brb31313-bib-0011){ref-type="ref"}). The phenotypes are variable subjecting to interactions between genetic mutations and environmental exposure (Kaye & Moser, [2004](#brb31313-bib-0008){ref-type="ref"}). Mutations in *GFAP*, *EIF2B1*, *ARSA*, *ABCD1,* and *MLC1* have been identified in leukodystrophies (Renaud, [2012](#brb31313-bib-0012){ref-type="ref"}). Discovery of additional pathogenic genes may facilitate diagnosis and treatment of leukodystrophies.

In this study, we reported a Chinese patient who was diagnosed as adult‐onset leukodystrophy. We unveiled a unique homozygous mutation in alanyl‐transfer RNA (tRNA) synthetase 2 (*AARS2*) (OMIM \#612035) in this patient.

2. CASE PRESENTATION {#brb31313-sec-0006}
====================

The patient was a 44‐year‐old Chinese man who was born healthy and developed normally until the age of 40 when he felt difficult to walk straight. The patient displayed cognitive decline and behavioral abnormality when he first sought medical advices associated with this discomfort at the age of 43 at the Second Affiliated Hospital and Yuying Children\'s Hospital, Wenzhou Medical University. Neurological examinations revealed bilateral cerebellar ataxia and generalized hyperreflexia. The Mini‐Mental State Examination score of the patient was 12/30. His muscle bulk, tone, strength, and sensory function were normal. No abnormality in electrocardiogram and echocardiography was found. No endocrine disorder was detected. The Laboratory parameters including plasma lactate, complete blood count, and cerebrospinal fluid protein content were normal. His parents are non‐consanguineous. His grandparents, parents, and his elder brother did not show any neurological or psychiatric problems.

The T1‐ and T2‐weighted image of brain magnetic resonance imaging (MRI) exhibited extensive symmetric periventricular white matter abnormalities with slight ventricular system enlargement and sulci widening. The midline structure remained unchanged (Figure [1](#brb31313-fig-0001){ref-type="fig"}a,b). Multiple segments of high signal in the corpus callosum were detected in the sagittal view of T2‐weighted image (Figure [1](#brb31313-fig-0001){ref-type="fig"}c). Analyses by fluid attenuated inversion recovery (FLAIR) showed hyperintensity in the deep and periventricular white matter, indicating white matter rarefaction (Figure [1](#brb31313-fig-0001){ref-type="fig"}d). Diffusion‐weighted imaging (DWI) showed sporadic restricted diffusion abnormalities in periventricular white matter (Figure [1](#brb31313-fig-0001){ref-type="fig"}e). No enhanced signal was found in contrast enhanced MRI (CEMRI; Figure [1](#brb31313-fig-0001){ref-type="fig"}f). Magnetic resonance spectroscopy (MRS) showed a relatively high level of choline and low level of *N*‐acetylaspartate in the left periventricular brain tissue (Figure [1](#brb31313-fig-0001){ref-type="fig"}g), where the T2‐weighted hyperintensity was detected (Figure [1](#brb31313-fig-0001){ref-type="fig"}b).

![Brain magnetic resonance imaging (MRI) of the patient. (a) T1‐weighted image, showing hypointensity of periventricular white matter. (b) T2‐weighted image, showing hyperintensity in the deep and periventricular white matter. (c) Sagittal view of T2‐weighted image, showing multiple segments of high signal in the corpus callosum. (d) Fluid attenuated inversion recovery (FLAIR), showing hyperintensity in the deep and periventricular white matter. (e) Diffusion‐weighted imaging (DWI), showing sporadic restricted diffusion abnormalities in periventricular white matter. (f) Contrast enhanced MRI (CEMRI), showing no enhanced signal. (g) Magnetic resonance spectroscopy (MRS), showing high levels of choline and low levels of *N*‐acetylaspartate in the left periventricular brain tissue. Arrows indicate the lesion sites or abnormal signals](BRB3-9-e01313-g001){#brb31313-fig-0001}

Exome sequencing revealed that the patient carried a homozygous mutation in *AARS2*, that is, c. 452T\>C (p. M151T). The mutation was confirmed by Sanger sequencing of his blood DNA (Figure [2](#brb31313-fig-0002){ref-type="fig"}a). The patient\'s father passed away at the age of 62 with no record of neurological disorders. We sequenced and analyzed the *AARS2* genotype of his mother and elder brother. The results showed that both of them were heterozygous (Figure [2](#brb31313-fig-0002){ref-type="fig"}b,c). Thus, this patient in principle maternally and paternally inherited the mutation to be homozygous (Figure [3](#brb31313-fig-0003){ref-type="fig"}).

![Sanger sequencing of the patient and his family members. (a) Homozygous mutation of C. 452T\>C in *AARS2* in the patient. (b‐c) Heterozygous mutation of C. 452T\>C in his mother (b) and brother (c). (d) Schematic location of the C. 452T\>C mutation in *AARS2*](BRB3-9-e01313-g002){#brb31313-fig-0002}

![Pedigree of the family. Arrow indicates the patient; question mark indicates non‐sequence](BRB3-9-e01313-g003){#brb31313-fig-0003}

The mutation was missense and localized in the exon 3 of *AARS2* (Figure [2](#brb31313-fig-0002){ref-type="fig"}d). There was no record of this mutation in dbSNP (<https://www.ncbi.nlm.nih.gov/SNP/>). The mutation was "probably damaging" as predicted by PolyPhen‐2 (<http://genetics.bwh.harvard.edu/pph2/>) and ascribed to the category of "affected protein function" based on SIFT (<http://sift.jcvi.org>).

Donepezil at the dose of 5 mg/day was prescribed to the patient for a duration of 1 month. Regular exercise such as walking was suggested. No significant improvement in cognitive function was observed in his follow‐up visits.

3. DISCUSSION {#brb31313-sec-0007}
=============

Leukoencephalopathy is a broad term that predominantly affects the white matter in association with multiple types of disorders, including infectious, inflammatory, vascular, and hereditary (Costello, Eichler, & Eichler, [2009](#brb31313-bib-0001){ref-type="ref"}; Vanderver et al., [2015](#brb31313-bib-0015){ref-type="ref"}). Leukodystrophy is generally referred to the hereditary type of leukoencephalopathy (Vanderver et al., [2015](#brb31313-bib-0015){ref-type="ref"}), and there is no effective treatment. In this study, we reported a unique case of adult‐onset leukodystrophy with a homozygous mutation of c. 452T\>C (p. M151T) in *AARS2*.

*AARS2* encodes mitochondrial alanyl‐tRNA synthetase, which is responsible for the aminoacylation between alanine and the tRNA during translation in the mitochondria. Deficiency in aminoacyl‐tRNA synthetases is known to contribute to mitochondrial diseases in association with a wide spectrum of clinical phenotypes (Fuchs et al., [2018](#brb31313-bib-0005){ref-type="ref"}; Konovalova & Tyynismaa, [2013](#brb31313-bib-0009){ref-type="ref"}). The AARS2 protein contains an editing and an aminoacylation domain, and mutations site‐specifically change its function in the catalysis of aminoacylation (Euro et al., [2015](#brb31313-bib-0004){ref-type="ref"}).

*AARS2* mutations were first identified in infantile mitochondrial cardiomyopathy in 2011 (Gotz et al., [2011](#brb31313-bib-0006){ref-type="ref"}), and later found to cause two different phenotypic disorders: severe infantile cardiomyopathy and adult‐onset leukodystrophy (Dallabona et al., [2014](#brb31313-bib-0002){ref-type="ref"}). Strikingly, no cardiopathy is present in adult‐onset leukodystrophy as suggested in our patient and 15 other reported cases (Table [1](#brb31313-tbl-0001){ref-type="table"}) (Dallabona et al., [2014](#brb31313-bib-0002){ref-type="ref"}; Hamatani et al., [2016](#brb31313-bib-0007){ref-type="ref"}; Lee et al., [2017](#brb31313-bib-0010){ref-type="ref"}; Lynch et al., [2016](#brb31313-bib-0011){ref-type="ref"}; Szpisjak et al., [2017](#brb31313-bib-0013){ref-type="ref"}). To date, all of the infantile cardiomyopathy exhibit a founder mutation, c. 1774C\>T (p. R592W), which is located in the editing domain and severely compromises the aminoacylation activity of AARS2 (Euro et al., [2015](#brb31313-bib-0004){ref-type="ref"}). In comparison, mutations in adult‐onset leukodystrophy include combinations of two missense mutations in the aminoacylation domain, a missense mutation in the aminoacylation domain with a truncating mutation, and other combinations. These mutations can be classified into three categories of activity impairment based on structural analyses, that is, loss of function, severely impaired, and moderate impaired (Euro et al., [2015](#brb31313-bib-0004){ref-type="ref"}). The extent of reduced aminoacylation activities may lead to differential phenotypes.

###### 

Characteristics of adult‐onset leukodystrophy induced by *AARS2* mutations

  ----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Report                                                          Sex           Race        Family history       Age at onset[a](#brb31313-note-0003){ref-type="fn"}   Age at death                              Initial neuropsychiatric symptoms       Cognitive decline   Psychiatric symptoms   Pyramidal symptoms   Extrapyramidal sign   Cerebellar symptoms   Dystonia/Epilepsy   Ovarian failure                                                                                            Mutation sites
  --------------------------------------------------------------- ------------- ----------- -------------------- ----------------------------------------------------- ----------------------------------------- --------------------------------------- ------------------- ---------------------- -------------------- --------------------- --------------------- ------------------- ---------------------------------------------------------------------------------------------------------- --------------------------------------------------------------------------------------
  Lynch et al. ([2016](#brb31313-bib-0011){ref-type="ref"})       F             NA          NA                   early 40s                                             NA                                        calculation, anxiety                    \+                  \+                     \+                   NA                    \+                    NA                  \+                                                                                                         c\. 1041−1G\>A (Exon 6[b](#brb31313-note-0004){ref-type="fn"})/c. 595C\>T (p. R199C)

  M                                                               Turkey        \+          late 30s             NA                                                    neuropsychiatric and behavioral changes   \+                                      \+                  NA                     \+                   NA                    NA                    M                   c\. 1188G\>A (Exon 8[b](#brb31313-note-0004){ref-type="fn"})/c. 1709delG (p. G570Afs\*21)                  

  M                                                               Turkey        \+          Mid‐20s              1 year[c](#brb31313-note-0005){ref-type="fn"}         neurodegenerative syndrome                NA                                      −                   \+                     NA                   NA                    NA                    M                   c\. 1188G\>A (Exon 8[b](#brb31313-note-0004){ref-type="fn"})/c. 1709delG (p. G570Afs\*21)                  

  M                                                               South Asian   −           middle adolescence   late adolescence                                      psychiatric symptoms                      NA                                      \+                  \+                     \+                   \+                    NA                    M                   c\. 892_894del (p. 298_298delQ)/c. 2234_2235del (p. S745Cfs\*60)                                           

  M                                                               Turkey        −           Mid‐40s              1 year[c](#brb31313-note-0005){ref-type="fn"}         dystonia, dysarthria                      \+                                      \+                  \+                     \+                   NA                    Dystonia              M                   c\. 595C\>T (p. R199C)/c. 595C\>T (p. R199C)                                                               

  Szpisjak et al. ([2017](#brb31313-bib-0013){ref-type="ref"})    M             Caucasian   −                    18                                                    NA                                        behavioral changes                      \+                  \+                     \+                   \+                    NA                    ‐                   M                                                                                                          c\. 578T\>G (p. L193\*)/c. 595C\>T (p. R199C)

  Dallabona et al. ([2014](#brb31313-bib-0002){ref-type="ref"})   F             NA          NA                   2                                                     NA                                        developmental delay                     \+                  \+                     NA                   \+                    \+                    NA                  \+                                                                                                         c\. 149T\>G (p. F50C)/c. 1561C\>T (p. R521\*)

  M                                                               NA            NA          infancy              NA                                                    nystagmus                                 \+                                      NA                  \+                     \+                   \+                    Dystonia              M                   c\. 2893G\>A (p. G965R)/c. 1213G\>A (p. E405K)                                                             

  F                                                               NA            NA          33                   NA                                                    depression, cognitive deterioration       \+                                      \+                  NA                     \+                   NA                    Epilepsy              \+                  \[c. 1609C\>T (p. Q537\*)+c. 2350del (p. E784Sfs\*9)\]/ \[c. 595C\>T (p. R199C)+c. 2188G\>A (p. V730M)\]   

  F                                                               NA            NA          24                   28                                                    tremor                                    \+                                      \+                  \+                     \+                   \+                    Dystonia              \+                  c\. 230C\>T (p. A77V)/\[c. 595C\>T (p. R199C)+c. 2188G\>A (p. V730M)\]                                     

  F                                                               NA            NA          40                   46                                                    depression, cognitive deterioration       \+                                      \+                  −                      −                    −                     ‐                     \+                  \[c. 595C\>T (p. R199C)+c. 2188G\>A (p. V730M)\]/c. 390_392del (p. F131del)                                

  F                                                               NA            NA          22                   NA                                                    gait problems                             −                                       \+                  \+                     NA                   \+                    NA                    \+                  \[c. 595C\>T (p. R199C)+c. 2188G\>A (p. V730M)\]/c. 2611dup (p. T871Nfs\*21)                               

  Hamatani et al. ([2016](#brb31313-bib-0007){ref-type="ref"})    F             Japanese    −                    30                                                    NA                                        cognitive decline, abnormal behaviors   \+                  \+                     \+                   \+                    \+                    NA                  \+                                                                                                         c\. 1145C\>A (p. T382K)/c. 2255 + 1G\>A (?)

  Lee et al. ([2017](#brb31313-bib-0010){ref-type="ref"})         F             Korean      \+                   35                                                    NA                                        cognitive impairment                    \+                  NA                     \+                   \+                    \+                    NA                  \+                                                                                                         c\. 963C\>A (p. Y321\*)/c. 452T\>C (p. M151T)

  M                                                               Korean        \+          35                   NA                                                    mistakes in machine\                      \+                                      NA                  \+                     NA                   \+                    Dystonia              M                   c\. 963C\>A (p. Y321\*)/c. 452T\>C (p. M151T)                                                              
                                                                                                                                                                       manipulation                                                                                                                                                                                                                                                                                                                 

  This study                                                      M             Chinese     −                    40                                                    −                                         difficult to walk                       \+                  \+                     \+                   −                     \+                    ‐                   M                                                                                                          c\. 452T\>C (p. M151T)/c. 452T\>C (p. M151T)
  ----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

Abbreviations: F, female; M, male; NA, not available.

Onset of neuropsychiatric symptoms.

Exclusion of the indicated exon.

Died within 1 year of onset of the disease.
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Clinical manifestations of the 16 leukodystrophy patients carrying *AARS2* mutations include cognitive decline, psychiatric symptoms, pyramidal symptoms, extrapyramidal signs, cerebellar symptoms, dystonia, and epilepsy (Table [1](#brb31313-tbl-0001){ref-type="table"}). These mutations are missense, nonsense, or frameshift by nature. Two of them are homozygous, including a case from Turkey, c. 595C\>T (p. R199C) (Lynch et al., [2016](#brb31313-bib-0011){ref-type="ref"}), and the c. 452T\>C (p. M151T) being reported herein. The probability for this case to occur is rather small given that his biological parents are non‐consanguineous. The mutation was previously reported in a pair of Korean brother‐sister twin, despite having compound heterozygous mutations additionally bearing a nonsense mutation site, c. 963C\>A (p. Y321\*) (Lee et al., [2017](#brb31313-bib-0010){ref-type="ref"}). Due to the small number of reported cases, it is difficult to correlate these mutations with specific clinical phenotypes. Interestingly, although the male patients are absent from any endocrine diseases and hypogonadism, all of the females are diagnosed with ovarian failure, suggesting that analysis of the *AARS2* gene should be prioritized when this sign is displayed in female patients.

4. CONCLUSION {#brb31313-sec-0008}
=============

In summary, we herein report a Chinese male patient of adult‐onset leukodystrophy carrying a c. 452T\>C (p. M151T) homozygous mutation in *AARS2*. It is autosomal recessive based on genotypic analyses of his family members. Our data provide further evidence that mutations of *AARS2* are implicated in adult‐onset leukodystrophy.
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